Recruiting
Phase 1
Alzheimer's Disease and Faecal Microbiota Transplantation -a Pilot Study
About this study
The goal of this study is to assess the feasibility and safety of faecal microbiota transplantation for Alzheimer's disease.
- Condition
- Alzheimer s Disease, Faecal Microbiota Transplantation (FMT)
- Tested
- Biological: Preprocessed thawed donor FMT
- Sponsor
- University Hospital of North Norway
Who can join
- Age
- 18 years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 5
- Minimum age: 18 years
- Study condition: Alzheimer s Disease, Faecal Microbiota Transplantation (FMT)
- Alzheimer's dementia mild to moderate stage
- Presence of Alzheimer pathology core 1 biomarkers as defined by National Institute on Aging-Alzheimer's Association (NIA-AA) criteria (2024)
- Capable of giving informed consent
Exclusion 17
- Contraindications for colonoscopy examination
- Contraindications for Magnetic Resonance Imaging (MRI)
- Life expectancy \< 1 year
- Clinical frailty scale 7 or more
- History of seizure disorder
- History of brain tumour or intracranial bleed
- Major psychiatric disorder such as schizophrenia, bipolar disorder, or major depressive disorder
- Alcohol or substance abuse
- Decompensated heart disease
- Malignancy
- Current use of anticoagulant treatment (dual acting oral anticoagulant or warfarin)
- Pregnant or planning pregnancy
- Colonic adenomas over 1 cm, tumours or signs of active colitis on colonoscopy
- Status after colectomy or hemicolectomy
- Inflammatory bowel disease
- Immunocompromised individual
- Receiving biological/antibody treatment
Where
1 site, 1 recruiting
University Hospital of North Norway, Tromsø
Tromsø, Troms, Norway
Contact
-
Mona Dixon Gundersen, MBChB, PhD
+47 77798916 mona.dixon.gundersen@unn.no
Potential match only. Final eligibility is determined by the study team.